Hyperosmolar Hyperglycemic State

Hyperosmolar hyperglycemic state (HHS), formerly called hyperosmolar hyperglycemic nonketotic coma (HHNC), is a life-threatening metabolic emergency characterized by severe hyperglycemia (typically >600 mg/dL), profound dehydration, and elevated serum osmolality (>320 mOsm/kg) with minimal or absent ketosis. HHS represents one of the two major acute hyperglycemic crises in diabetes, distinguished from diabetic ketoacidosis (DKA) by the preservation of sufficient endogenous insulin secretion to suppress lipolysis while remaining inadequate for glucose utilization. The condition predominantly affects elderly patients with type 2 diabetes mellitus (mean age 60 years) and carries a mortality rate of 5-15%, substantially higher than DKA due to the older patient demographic and associated comorbidities. Recognition and appropriate management are critical for boards because HHS requires aggressive fluid replacement, careful electrolyte monitoring, and recognition of the often-precipitating acute medical illness that distinguishes this condition from DKA management strategies.

HHS results from a complex interplay of inadequate insulin secretion and action, osmotic diuresis, and progressive dehydration. Unlike DKA where insulin deficiency is profound and near-total, HHS occurs in the setting of residual but insufficient insulin secretion—enough to suppress hepatic ketogenesis through inhibition of adipose tissue lipolysis, yet inadequate to facilitate peripheral glucose uptake or suppress hepatic glucose production.

The pathophysiology is initiated by severe hyperglycemia, which exceeds the renal threshold for glucose reabsorption (typically 180 mg/dL, but overwhelmed at extreme levels). Filtered glucose acts as an osmotic agent in the renal tubule lumen, preventing water reabsorption and creating an osmotic diuresis. This leads to urinary losses of 5-10 liters of hypotonic fluid daily, resulting in profound intracellular and extracellular volume depletion (estimated total body water deficit of 8-10 L). Volume contraction triggers compensatory mechanisms including activation of the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS), both of which increase hepatic glucose production and impair glucose clearance, creating a vicious cycle of worsening hyperglycemia.

In HHS, endogenous insulin levels are typically 5-15 mU/L—higher than in DKA (where levels approach zero) but below the 25-50 mU/L needed for normal glucose homeostasis. This intermediate insulin level is sufficient to exert anti-lipolytic effects on adipose tissue (suppressing hormone-sensitive lipase activity and free fatty acid release), thereby preventing the massive lipolysis that characterizes DKA. Consequently, plasma free fatty acid concentrations remain relatively low (typically 1-2 mEq/L versus 3-5 mEq/L in DKA), preventing overwhelming substrate delivery to hepatic mitochondria and the subsequent production of ketone bodies. Without significant ketone generation, bicarbonate remains preserved and arterial pH remains normal or only mildly reduced, resulting in the absence of metabolic acidosis that would otherwise trigger compensatory hyperventilation and the characteristic fruity breath odor of DKA.

Despite inadequate peripheral glucose utilization, the liver continues to produce glucose through both glycogenolysis and gluconeogenesis. With insufficient circulating insulin to suppress hepatic glucose output (insulin inhibits both pathways through phosphorylation of key regulatory enzymes including phosphofructokinase-2 and acetyl-CoA carboxylase), and with elevated counter-regulatory hormones (glucagon, catecholamines, cortisol, growth hormone) released in response to volume depletion, hepatic glucose production can reach 4-5 times normal levels. Concurrently, severe hyperglycemia and dehydration impair glucose utilization in peripheral tissues—both through reduced insulin signaling and through reduced glucose transporter activity in insulin-independent tissues (such as brain and renal tubules) when intracellular osmolality becomes severely elevated.

As glucose accumulates in the extracellular space without proportional water accumulation, serum osmolality rises dramatically. The measured osmolality can reach 320-380 mOsm/kg (normal: 285-295). Calculation of effective osmolality (2[Na+] + glucose/18 + BUN/2.8) reveals that glucose contributes substantially to the osmotic gradient. This elevated osmolality creates a powerful osmotic gradient favoring water movement from the intracellular to extracellular compartment. Intracellular dehydration becomes profound, with particular consequences in the central nervous system—brain cell dehydration and swelling of intracellular osmolytes can lead to altered consciousness, seizures, and potential cerebral edema as osmolality is corrected too rapidly.

High glucose concentrations themselves produce insulin resistance through multiple mechanisms: (1) desensitization of insulin signaling pathways, (2) impaired glucose transporter translocation, and (3) accumulation of toxic glucose metabolites. Additionally, extreme hyperosmolality impairs cellular function, reducing the effectiveness of available insulin. This creates a self-perpetuating cycle where severe hyperglycemia and dehydration worsen insulin resistance, perpetuating the metabolic derangement.

The foundational risk is pre-existing type 2 diabetes, present in 50-60% of HHS patients at diagnosis and present in nearly all by disease recognition. HHS typically develops in patients with either undiagnosed diabetes or with poor glycemic control due to medication non-adherence, inadequate insulin dosing, or progressive beta-cell dysfunction. Advanced age (>60 years) is a critical risk factor, as aging is associated with impaired thirst mechanisms, reduced renal function, and greater susceptibility to concurrent acute illness.

A precipitating acute illness is identified in 80-90% of HHS cases, substantially higher than in DKA. Common precipitants include: (1) infection (urinary tract infection, pneumonia, sepsis—accounting for 30-40% of cases), (2) acute coronary syndrome or stroke, (3) medications (particularly glucocorticoids, thiazide diuretics, atypical antipsychotics, SGLT2 inhibitors in rare cases), (4) surgical stress or trauma, and (5) renal or hepatic failure reducing medication clearance. The stress response from these acute illnesses causes massive release of counter-regulatory hormones (glucagon, catecholamines, cortisol), simultaneously worsening hyperglycemia while causing volume depletion through increased urinary losses, vomiting, or reduced intake.

Elderly patients have impaired thirst sensation and may have reduced access to water due to immobility, cognitive impairment, or social circumstances. Patients with impaired consciousness from stroke or other conditions cannot communicate thirst or access fluids. Nursing home residents have documented higher rates of HHS, partly attributable to inadequate fluid provision. Additionally, patients who reduce fluid intake due to nausea or gastrointestinal illness cannot compensate for osmotic diuresis.

Non-adherence with insulin or oral antidiabetic agents is a critical modifiable risk factor. Additionally, specific medications precipitate or worsen HHS: glucocorticoids (increase hepatic glucose production and impair insulin secretion), thiazide diuretics (impair insulin secretion and promote volume depletion), loop diuretics (exacerbate dehydration), atypical antipsychotics (impair glucose metabolism), and potentially SGLT2 inhibitors (in euglycemic DKA, though normoglycemic HHS has been rarely reported).

Severe hyperglycemia exceeding the renal glucose threshold triggers glycosuria and osmotic diuresis. Patients experience polyuria, often with urine volumes exceeding 5-10 liters daily. The accompanying osmotic effect prevents water reabsorption, but patients attempt to compensate through polydipsia (excessive thirst-driven drinking). However, elderly patients with impaired thirst mechanisms or reduced access to fluids cannot maintain adequate oral intake, resulting in progressive dehydration. The lag between polyuria and reduced thirst/access creates a critical window where intravascular and intracellular volumes become profoundly depleted.

Altered consciousness represents a hallmark of HHS and occurs in 50-80% of presentations, ranging from confusion and lethargy to obtundation, seizures, or coma. The mechanism is multifactorial: (1) hyperosmolality-induced brain cell dehydration causing altered neurotransmitter function and reduced neuronal excitability, (2) reduced cerebral blood flow from volume depletion and hyperviscosity (elevated hemoglobin concentration from hemoconcentration), and (3) comorbid acute illness (stroke, myocardial infarction, infection/sepsis with delirium). The degree of consciousness impairment correlates with serum osmolality—osmolalities >350 mOsm/kg are associated with profound altered mental status, whereas osmolalities 320-350 may produce only mild confusion. This contrasts with DKA, where acidosis rather than osmolality primarily drives neurological symptoms; HHS patients may present with severe altered consciousness despite mild acidosis, a key distinguishing feature.

Profound total body water depletion of 8-10 liters (representing 15-20% of total body water in elderly patients) produces dramatic dehydration symptoms: severe thirst (in those capable of expressing it), dry mucous membranes, poor skin turgor, and orthostatic hypotension progressing to shock. Unlike mild dehydration, HHS-associated volume depletion is often catastrophic, with intravascular volume depletion sufficient to cause acute kidney injury, tissue hypoperfusion, and end-organ dysfunction. Elderly patients may present with non-specific complaints of weakness, fatigue, or functional decline before developing overt shock.

Tachycardia is nearly universal, often with heart rates 100-120 beats per minute reflecting sympathetic compensation. Hypotension (systolic <100 mmHg) indicates severe volume depletion and is associated with poor prognosis. Orthostatic hypotension (>20 mmHg drop in systolic pressure on standing) is present in most patients. Mucous membranes are characteristically dry, and skin turgor is severely reduced—pinched skin returns slowly to baseline. Axillary skin may be warm and dry (unlike the cold, clammy skin of cardiogenic shock), reflecting the intact cutaneous perfusion despite profound volume depletion. Jugular venous pressure is markedly reduced. Urine output is minimal in severe cases, reflecting both volume depletion-induced oliguria and progressive acute kidney injury.

Altered mental status on examination ranges from disorientation and confusion to complete unresponsiveness. Some patients present with focal neurological deficits (hemiparesis, hemianopia, aphasia) that initially suggest stroke but represent hyperosmolar encephalopathy or coincident acute stroke. Seizures may occur (present in 5-15% of cases), reflecting both acute hyperosmolality and metabolic derangements. Some patients demonstrate reflexic hyperreflexia and increased tone. Typically, Kussmaul respirations (the deep, labored breathing characteristic of DKA) are notably absent or mild in HHS since metabolic acidosis is absent—this is a critical distinguishing feature from DKA.

While hyperglycemia is the hallmark, rare cases of euglycemic HHS have been reported, particularly in patients concurrently receiving SGLT2 inhibitors or in those with severe illness causing reduced oral intake. In these cases, glucose levels may be only mildly elevated (250-400 mg/dL) while osmolality remains severely elevated due to accumulated solutes other than glucose. These presentations present diagnostic challenges and may be missed if HHS is assumed to require glucose >600 mg/dL.

Plasma glucose typically exceeds 600 mg/dL, with many patients presenting at 800-1200 mg/dL or higher. However, diagnostic criteria recognize glucose as low as 250-300 mg/dL in some definitions when accompanied by profound osmolality elevation. For USMLE purposes, severe hyperglycemia (>600 mg/dL) is the hallmark. Measurement should be obtained via plasma glucose (arterial or venous); capillary glucose measurements (fingerstick) may be inaccurate at extreme values due to instrument limitations and should be confirmed with laboratory measurement.

Effective serum osmolality >320 mOsm/kg is a defining criterion for HHS (normal: 285-295 mOsm/kg). Osmolality should be calculated using the formula: Osmolality = 2[Na+] + glucose/18 + BUN/2.8, where sodium is in mEq/L, glucose and BUN are in mg/dL. Measured osmolality may differ from calculated osmolality; a gap between measured and calculated osmolality (osmolar gap >10 mOsm/kg) suggests presence of additional osmotically active substances (ethanol, methanol, ethylene glycol, mannitol) and should prompt investigation for alternative toxidromes. Osmolality correlates directly with severity of altered mental status and prognosis.

Unlike DKA where plasma ketones are markedly elevated and beta-hydroxybutyrate (the predominant ketone) is typically >3 mmol/L, HHS demonstrates absent or minimal ketosis. Serum or urine ketones should be negative or trace (not large or moderate as in DKA). Arterial pH >7.30 and serum bicarbonate >15 mEq/L—representing absence of significant metabolic acidosis—distinguish HHS from DKA. This is a critical diagnostic differentiator: a patient with severe hyperglycemia, hyperosmolality, but minimal ketosis and preserved pH has HHS, not DKA. Occasionally, mild ketonemia (1-2 mmol/L) may be present as a response to volume depletion and lipolysis, but this remains substantially lower than in DKA.

The diagnostic criteria for HHS, as defined by the American Diabetes Association, require: